CALC icon

CalciMedica

2.76 USD
-0.01
0.36%
At close Dec 20, 4:00 PM EST
After hours
2.76
+0.00
0.00%
1 day
-0.36%
5 days
1.10%
1 month
-20.00%
3 months
-44.69%
6 months
-46.92%
Year to date
-10.10%
1 year
-10.10%
5 years
-98.81%
10 years
-98.81%
 

About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

Employees: 13

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

15% more capital invested

Capital invested by funds: $11.8M [Q2] → $13.6M (+$1.77M) [Q3]

14% more funds holding

Funds holding: 21 [Q2] → 24 (+3) [Q3]

0.81% more ownership

Funds ownership: 27.68% [Q2] → 28.49% (+0.81%) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$13
371%
upside
Avg. target
$14.50
425%
upside
High target
$16
480%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
LUCID CAPITAL MARKETS
Dev Prasad
0% 1-year accuracy
0 / 3 met price target
371%upside
$13
Buy
Initiated
17 Dec 2024
HC Wainwright & Co.
Joseph Pantginis
21% 1-year accuracy
79 / 384 met price target
480%upside
$16
Buy
Reiterated
14 Nov 2024

Financial journalist opinion

Neutral
PRNewsWire
1 month ago
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
LA JOLLA, Calif. , Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
Neutral
PRNewsWire
1 month ago
CalciMedica Announces Presentations at Upcoming Medical Meetings
Prof. Robert Sutton to  deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting LA JOLLA, Calif. , Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at  the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.
CalciMedica Announces Presentations at Upcoming Medical Meetings
Neutral
PRNewsWire
1 month ago
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE trial in acute kidney injury (AKI) and in Phase 2 portion of CRSPA trial in asparaginase-induced pancreatic toxicity (AIPT); data from both trials expected in 2025 Following a public offering in October, the Company's cash position is expected to fund current operations into the first half of 2026 LA JOLLA, Calif. , Nov. 13, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2024 and provided clinical and corporate updates.
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Neutral
PRNewsWire
1 month ago
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Stephen Bardin as Chief Financial Officer and the planned departure of Daniel Geffken, Interim Chief Financial Officer upon filing the Company's third quarter financial statements.
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
Neutral
PRNewsWire
1 month ago
CalciMedica Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the pricing of an underwritten public offering of 2,720,000 shares of its common stock at a price to the public of $3.75 per share.
CalciMedica Announces Pricing of Public Offering of Common Stock
Neutral
PRNewsWire
1 month ago
CalciMedica Announces Proposed Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it has commenced an underwritten public offering of its shares of common stock.
CalciMedica Announces Proposed Public Offering of Common Stock
Neutral
PRNewsWire
1 month ago
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m.
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
Neutral
PRNewsWire
1 month ago
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m.
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Neutral
PRNewsWire
2 months ago
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of a late-breaking abstract for a plenary presentation by Prof.
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
Neutral
PRNewsWire
3 months ago
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Charts implemented using Lightweight Charts™